Distribution of Cholecystokinin-B Receptor Genotype Between Patients With Pancreatic Cancer and Controls and Its Impact on Survival

Pancreas - United States
doi 10.1097/mpa.0000000000000263
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Cholecystokinin Receptor-Targeted Polyplex Nanoparticle Inhibits Growth and Metastasis of Pancreatic Cancer

Cellular and Molecular Gastroenterology and Hepatology
HepatologyGastroenterology
2018English

Impact of the Treatment of Pancreatic Exocrine Insufficiency on Survival of Patients With Unresectable Pancreatic Cancer: A Retrospective Analysis

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Purification of the Pancreatic Cholecystokinin Receptor

Regulatory Peptides
1989English

A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma

Nucleic Acid Therapeutics
BiochemistryMolecular MedicineDrug DiscoveryGeneticsMolecular Biology
2017English

Impact of Resection Margin Status on Recurrence and Survival in Pancreatic Cancer Surgery

British Journal of Surgery
Surgery
2019English

Impact of Statin Use on Survival in Patients Undergoing Resection for Early-Stage Pancreatic Cancer

American Journal of Gastroenterology
HepatologyGastroenterology
2015English

Improved Relapse-Free Survival on Aromatase Inhibitors in Breast Cancer Is Associated With Interaction Between Oestrogen Receptor-Α and Progesterone Receptor-B

British Journal of Cancer
Cancer ResearchOncology
2018English

The Effect of Combined Treatment Methods on Survival and Toxicity in Patients With Pancreatic Cancer

Medicina
Medicine
2007English

Table 3: Distribution of Genotype and Allele Frequencies of CYBA 242 C/T Polymorphism in Controls and Breast Cancer Patients.

English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy